Use of artificial intelligence (AI) in bioprocessing is set to increase. According to a Deloitte survey, biopharma is undergoing a “digital transformation” with 58% of executives quizzed identifying the adoption of innovative technologies, AI, and automation as a top priority.
Some of the advantages of AI for biopharmaceutical manufacturers are obvious, says Fabian Mohr, an advanced manufacturing systems researcher at the Massachusetts Institute of Technology (MIT). He cites AI’s ability to predict the impact processing changes will have on product critical quality attributes (CQAs) as an example.